RFA-DC-25-003: Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (U01, Clinical Trial Required)

RFA-DC-25-003: Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (U01 Clinical Trial Required)

NIDCD’s RFA-DC-25-003 was a specialized federal biomedical funding opportunity for teams developing in vivo imaging of the living human inner ear. Its final listed application receipt date was October 1, 2026, and the notice expired October 2, 2026. The NIH/NIDCD notice lists no later receipt date, and no successor U01 round is announced on the official notice. This page is therefore a historical reference, not an open application listing. The companion R01 notice (RFA-DC-25-005) was a separate funding opportunity with its own terms and dates.

For teams working on hearing and balance disorders, the NOFO joined imaging technology development to clinical outcomes. It asked whether a project could move a method toward meaningful human use and whether its clinical trial design was rigorous and feasible. That purpose remains useful context for researchers reviewing the prior call, but the expired announcement cannot be used to submit an application now. Applicants considering a future proposal need to consult the official funding notice in force for that cycle.

What this opportunity is and what it is not

The notice was titled Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (U01 Clinical Trial Required). It was a reissue of earlier RFA-DC-24-005 and was administered by NIH through the National Institute on Deafness and Other Communication Disorders (NIDCD).

What it supports:

• investigator-initiated high-risk clinical trials aimed at in vivo structural and functional imaging in the living human inner ear;
• new imaging modalities, or substantial improvement of existing modalities, to improve spatial and functional resolution;
• imaging probes/contrast agents that can improve localization or diagnostic utility;
• translation pathways into clinical settings, not purely bench-only proof-of-concept work.

What it does not support:

• non-clinical trials that do not satisfy the U01 criteria;
• low-risk studies that should be considered under the companion RFA-DC-25-005 (R01 clinical-trial optional);
• proposals that are not aligned to NIDCD mission areas.

The NOFO points to a broad technical vision: high-resolution structural and functional imaging that materially improves our ability to visualize auditory and vestibular pathology in ways that can alter diagnosis, treatment planning, and care pathways.

Key opportunity details at a glance

Why teams pursue this call

The call was designed for teams able to explain how an imaging advance could affect clinical care. Novelty alone was insufficient: an application had to show a development-to-translation path and meet this U01’s clinical-trial requirements. This section describes the prior call’s intended fit and is not evidence that NIDCD currently accepts applications under this number.

Typical applicants that do well include:

• translational imaging scientists with established partnerships in otology, neuroradiology, and clinical trial infrastructure;
• interdisciplinary groups linking imaging physics, data science, signal processing, and ear-specific clinical endpoints;
• teams already thinking about regulatory readiness, data governance, and study operations in clinical environments.

Why this is a strong strategic call:

1. It bridges technology development with an NIH-defined clinical trial standard.
2. It opens a path for high-risk ideas that need institutional oversight and staged validation.
3. It gives reviewers a clear lens: feasibility + rigor + path to clinical usefulness.
4. It is not narrowly local or regional; the eligibility set is broad enough for domestic and foreign institutions, with explicit provisions for non-U.S. collaborators.

Who is eligible

For the expired cycle, the NOFO allowed applications from these organizational types:

• public and private higher-education institutions;
• nonprofits (with and without 501(c)(3) status);
• for-profit entities and small businesses;
• local and state governments, eligible federal entities, and U.S. territories or possessions;
• independent school districts, public housing authorities, Indian housing authorities, and tribal organizations;
• faith-based/community organizations and regional entities;
• non-domestic entities (foreign organizations), plus foreign components of U.S. organizations.

A few constraints defined the expired call:

• It was a clinical-trial-required opportunity. A proposal that was not a clinical trial was not eligible under this U01.
• The trial has to meet at least one high-risk criterion: need for FDA oversight (IND/IDE), higher-risk design features, or a phase III-style efficacy objective.
• The application could propose only one clinical trial. An application missing milestones and contingency plans for delays, or any of the five required Research Strategy points, was listed as nonresponsive and would not be reviewed.

For NIH systems compliance, applicants for that cycle had to complete and maintain required registrations before submission:

• SAM registration (with renewal expectations), including the UEI and, for foreign organizations, an NCAGE code;
• eRA Commons;
• Grants.gov profile and linked access.

For that cycle, the NOFO said registrations could take six weeks or more and had to be complete before submission. A PD/PI needed an eRA Commons account, which could take up to two weeks to obtain. The notice said late or incomplete registrations were not valid reasons for a late submission. Those instructions describe the expired cycle; future NIH submissions must follow the applicable current NOFO and application guide.

Practical eligibility check for your team

Before drafting, validate this list:

1. Do you have an intervention pathway that qualifies as a U01-level trial?

   • FDA-relevant intervention, higher-risk method, or Phase III-style design?

2. Can you justify one clinical trial only per application?

   • The NOFO explicitly rejects proposals proposing more than one clinical trial.

3. Do you have a realistic translation plan?

   • The program is not for purely technical papers. You need a route from method development to clinical setting, with use-case and operational implications.

4. Do your institutional registrations work months in advance?

   • Start SAM, eRA Commons, and Grants.gov setup at least six weeks before submission, with extra time for a new PD/PI account.

5. Can your data-sharing and trial governance materials meet requirements?

   • Resource-sharing plans, data management plans, and subject-protection documentation are not optional extras.

If several answers are weak, this is likely not the first choice call for your concept until those elements are strengthened.

Application process and required materials in the expired cycle

The official notice instructed applicants to access the package through ASSIST, Grants.gov Workspace, or an institutional system-to-system (S2S) solution. Those were the submission routes for RFA-DC-25-003 while it was open; they do not reopen the expired cycle. The NOFO and the NIH Application Guide controlled form content, page limits, and attachments. Its preparation requirements fell into two connected areas:

1. Submission architecture track

   • eRA Commons account setup for PD/PI and org representative.
   • SAM.gov readiness, including registrations and identifiers.
   • Internal administrative sign-off on roles and PI account mapping.

2. Content track

   • SF424/R&R forms and attachments completed under the NIH Application Guide and this NOFO’s program-specific instructions.
   • Human subjects and clinical-trial details, including the intervention, population, endpoints, safety, and monitoring plans.
   • A Data Management and Sharing Plan for any application that will generate scientific data, plus required resource-sharing information.
   • FDA documentation for drug, biologic, or device interventions, as directed in the NOFO’s human-subjects and clinical-trials instructions.
   • Appendices only within the narrow limits stated in the Application Guide and NOFO.

The NOFO listed five required Research Strategy points. The first three concerned the technology and its translation; applicants also had to explain clinical use and conditions, and identify target pathologies and treatment consequences. In summary, the narrative needed to address:

• the specific imaging dimension(s) improved (spatial/temporal/functional);
• measurable resolution gains and their clinical relevance;
• translation timeline into awake-human clinical settings where relevant;
• intended clinical settings, conditions of use, and effects on care, management, or clinical decisions;
• the inner-ear pathology or clinical problem the method addressed and its implications for treatment.

For clinical trials, the notice emphasized an executable plan. An application needed milestones and contingency plans for delay, appropriate protections for participants, and a credible operational approach. Recruitment and retention plans had to include proactive strategies and community engagement. Read those requirements in the original NOFO rather than treating this historical summary as a complete submission checklist.

Timeline and how to read the expired deadlines

This opportunity has multiple listed receipt dates. The official schedule includes:

• June 3, 2025 (new and resubmission)
• October 1, 2025 (new and resubmission)
• June 3, 2026 (new and resubmission)
• October 1, 2026 (new and resubmission)

The last listed receipt date was October 1, 2026. Applications were due by 5 PM local time of the applicant organization, and the NOFO stated that no late applications would be accepted. The notice expired October 2, 2026. For applications received on the final listed date, NIH scheduled scientific merit review for March 2027, advisory council review for May 2027, and the earliest project start for July 2027. These are review and award milestones, not future application deadlines. Since the receipt date and notice expiration have passed, a team cannot submit under this notice now.

A planning sequence for a future, separately announced opportunity might involve the steps below, but these intervals were not official deadlines or guarantees in RFA-DC-25-003:

• Month 1–2: finalize mechanism fit and determine if your study genuinely meets U01 criteria.
• Month 2–3: lock trial hypothesis, endpoints, and inclusion logic; pre-register operational assumptions.
• Month 3–4: finalize PI roles, institutional agreements, and mandatory registrations.
  • Month 4–5: draft the NIH research forms, Data Management and Sharing Plan, human-subjects materials, and trial records.
• Month 5: internal mock-submission, compliance audit, and final submission.

The expired NOFO’s registration lead times and clinical-trial documentation requirements made early institutional review important. Anyone preparing a future application should verify the new notice’s receipt dates, instructions, eligible mechanisms, and forms before relying on this old planning sequence.

Common mistakes that could have made an application nonresponsive

1. Submitting as low-risk work under U01. The NOFO had an explicit partition: low-risk work that did not meet the U01 risk criteria belonged under companion R01 RFA-DC-25-005. A proposal needed to explain why its trial fit this U01.

2. Multiple trial concepts in one proposal. The rules allowed only one clinical trial per application.

3. No milestone and contingency design. For this call, milestone and contingency plans were required. Reviewers also assessed whether the proposed trial could be carried out as described.

4. Underestimating regulatory preparation. Missing FDA pathway thinking, inadequate clinical infrastructure, or unclear IRB or safety governance is typically judged as feasibility risk.

5. Ignoring required five research strategy prompts. These prompts are not cosmetic. They are directly tied to responsiveness.

6. Not complying with registration lead times. SAM/eRA/Grants.gov misalignment is one of the most common pre-review failures.

7. Treating this as an R01-style exploratory grant. Reviewers and program staff evaluated this as a structured cooperative agreement with active NIH involvement and strong execution demands.

Review expectations, scoring logic, and what reviewers like

The peer review path is standard NIH two-step review, but with high practical emphasis on trial quality. Reviewers evaluate scientific merit while simultaneously checking whether the proposal is implementable within timeline and budget.

Strong proposals usually stand out in four ways:

• Mechanistic and translational clarity: why this imaging technology is needed and where it changes diagnosis, management, or treatment.
• Trial-level discipline: milestone sequencing, contingency actions, and realistic enrollment and timeline logic.
• Measurement strategy: how data quality, imaging endpoints, and outcome validity are protected.
• Institutional readiness: teams that can demonstrate execution capability (not just technical brilliance) consistently score higher.

Common “good but losing” applications had deep technology but weak human-pathway reasoning. The call was intentionally clinical: technical merit had to connect to a plausible path for clinical implementation.

How a team could have prepared for the prior call

Use this as a practical sequence:

Step 1: Decide if your study belongs to U01 or companion R01

For the expired cycle, the U01 was intended for trials requiring FDA oversight, intended to formally establish efficacy, or involving potentially higher participant risk. Low-risk trials that met none of those criteria were directed to companion R01 RFA-DC-25-005. A future call may use different terms, so check its own eligibility and program contacts.

Step 2: Build the trial architecture first

Draft a short trial operations map before writing background sections:

• study population and recruitment source,
• imaging endpoint and endpoint validity,
• safety and monitoring chain,
• pre-implementation docs plan (IRB approvals, DSMB logic as relevant, case report framework, intervention procurement, SOPs).

Step 3: Translate technical claims into measurable gains

For each imaging promise, define the quantitative gain target and its clinical interpretation. A claim like “better resolution” must become “X-fold gain in practical diagnostic utility for Y pathology.”

Step 4: Lock governance and compliance dependencies

Map who has the administrative roles in SAM, eRA Commons, and Grants.gov, and confirm PI account readiness well before a future deadline. For this notice, organizational registrations had to be complete before submission; its registration guidance should not be assumed to govern a later call.

Step 5: Run a responsiveness pass

For this notice, the application had to meet these explicit response criteria:

• one clinical trial only,
• mission alignment,
• required strategy points,
• budget cap and justification,
• registration completeness,
• no prohibited application types.

Step 6: Write for reviewer workload

A strong reviewer can quickly tell whether your team knows the field and the clinical process. Use crisp sectioning. Show direct evidence of translational viability rather than listing disconnected aims.

FAQ

Is this only for U.S. institutions?

No. The NOFO explicitly allows non-domestic entities and foreign components in U.S. organizations. This is still a U.S.-administered NIH opportunity, so U.S. federal systems and eligibility mechanics still apply.

What was the final deadline?

The notice listed four receipt dates: June 3, 2025; October 1, 2025; June 3, 2026; and October 1, 2026. The final date has passed and the notice expired October 2, 2026. Its 2027 dates are review, council, and earliest-start milestones, not application deadlines. No later U01 receipt date appears in the official notice.

Were small businesses eligible for this cycle?

Yes. Small businesses were among the eligible organization types in the expired notice.

Was cost sharing required?

No. The NOFO stated that cost sharing was not required.

What is the funding amount?

For this expired cycle, NIDCD stated an intention to commit $3 million in FY 2025 for 2-4 awards across this notice and companion RFA-DC-25-005. Future-year amounts depended on annual appropriations, with $2 million planned in both FY 2026 and FY 2027. Each grant was to request less than $500,000 in direct costs per year unless NIDCD gave prior approval; the notice said an over-limit request should be discussed at least six weeks before the due date.

Can applicants include publications in appendices?

Only limited appendix materials are allowed. Publications are generally disallowed except narrow exclusions like blank questionnaires/surveys.

What happens after submission

If the application passes peer review, funding decisions then factor in peer review, available funds, and program priorities. Even strong science is not enough if the proposal is out of compliance or cannot pass initial administrative checks.

Typical compliance checkpoints include:

• successful eRA submission validation,
• institutional and PI registration verification,
• alignment with trial definitions and section requirements,
• potential federal checks against applicant responsibility records.

For an investigator considering a high-stakes application calendar, the key recommendation is to prioritize administrative readiness and trial operations design before polish of narrative prose.

Final fit assessment

If your group already has a defined clinical imaging protocol and can demonstrate operational capacity for a high-risk clinical trial, RFA-DC-25-003 is a targeted option. If you still have a technology concept without trial readiness, this NOFO will quickly expose execution gaps.

The practical bar is not simply novelty. It is “Can this project become a clinical process, on schedule, with auditable rigor, and with coherent management?” That framing should guide every section of your submission.

Official links

• Official NOFO page: https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-25-003.html
• Companion announcement reference (R01, clinical-trial-optional): https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-25-005.html
• NIDCD research page context: https://www.nidcd.nih.gov
• NIH portal and grant administration references linked from the NOFO: NIH ASSIST, eRA Commons, Grants.gov